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Placement of AoRTic TraNscathetER Valves
Martin B. Leon, M.D., Craig R. Smith, M.D., Michael Mack, M.D.,
D. Craig Miller, M.D., Jeffrey W. Moses, M.D.,
Lars G. Svensson, M.D., Ph.D., E. Murat Tuzcu, M.D.,
John G. Webb, M.D., Gregory Fontana, M.D., Raj Makkar, M.D.,
David Brown, M.D., Peter Block, M.D., Robert Guyton, M.D.,
Augusto D. Pichard, M.D., Joseph Bavaria, M.D.,
Howard Herrmann, M.D., Pamela Douglas, M.D., John Petersen, M.D.,
Jodi J. Akin, M.S., William N. Anderson, Ph.D.,
Duolao Wang, Ph.D., and Stuart Pocock, Ph.D. for the PARTNER Trial
Investigators
Background: Many patients with severe aortic stenosis (AS) and advanced
age or multiple co-morbidities may not be candidates for surgical aortic
valve replacement. Recently, transcatheter aortic valve implantation
(TAVI) has been suggested as a less invasive treatment in some “high risk”
AS patient subgroups. Although TAVI registry reports suggest improved
30-day clinical outcomes, thus far, there have been no studies in carefully
selected non-operable AS patients and no randomized controlled trials
using TAVI therapy in any AS patient population.
Methods: The PARTNER (Placement of AoRTic TraNscathetER Valves)
trial randomized (1:1) patients with severe AS (AVA 0.8cm2), cardiac
symptoms, and acceptable vascular access, who were deemed non-operable
by cardiac surgeons (predicted50% 30-day operative mortality or serious
irreversible morbidity) to either standard therapy or trans-femoral TAVI
using a balloon-expandable Edwards-SAPIEN™ bovine pericardial valve.
The primary endpoint was superiority in freedom from all-cause mortality
(1 year follow-up in all patients), over the duration of the study and the
co-primary endpoint was a hierarchical multiple pair-wise comparison of
time to all-cause mortality and time tofirst occurrence of repeat hospital-
ization due to valve or procedure-related clinical deterioration (Finklestein-
Schoenfeld method).
Results: 358 non-operable patients with severe AS were enrolled at 21
investigator sites (17 in the U.S. and 4 outside the U.S.) and were assigned
to be treated with TAVI (179 patients) or standard therapy (179 patients).
The patient population was extremely “high risk” for surgery: STS risk
score was11.86.2% and there were many clinical co-morbidities which
contributed to the determination of non-operable status, including porcelain
aorta (15.1%), chest wall radiation or deformity (14.7%), oxygen-depen-
dent respiratory insufficiency (23.8%), and severe frailty (27.9%). In ad-
dition to the primary endpoints, all secondary endpoints (including NYHA
functional class, core lab serial echo findings, 6-minute walk tests, and
procedure-related complications) will be available and reported at the time
of presentation.
Conclusions: PARTNER is the first randomized TAVI trial worldwide and
should address the important question of whether less invasive trans-femoral
TAVI is the preferred therapy in non-operable patients with severe AS.
A Large-Scale Randomized Comparison of Everolimus-Eluting and
Paclitaxel-Eluting Stents: Two-Year Clinical Outcomes from the
SPIRIT IV Trial
Gregg W. Stone, Manejeh Yaqub, Poornima Sood, Ali Rizvi,
William Newman, Kourosh Mastali, John C. Wang, Ronald Caputo,
Kyoko Hattori, Xiaolu Su, Charles A. Simonton, Alexandra J. Lansky,
Donald E. Cutlip, Krishnankutty Sudhir, and Dean J. Kereiakes
for the SPIRIT IV Investigators
Background: In the prospective, randomized SPIRIT IV trial, the
XIENCE V everolimus-eluting stent (EES) compared to the TAXUS EX-
PRESS2 paclitaxel-eluting stent (PES) resulted in significantly reduced
rates of the primary endpoint of target lesion failure [TLF; cardiac death,
target vessel myocardial infarction (MI) or ischemia-driven target lesion
revascularization (ID-TLR)] at 1-year follow-up. Treatment with EES also
resulted in a marked reduction in stent thrombosis and significantly fewer
MIs and ID-TLR events. Whether these results (particularly the low rate of
stent thrombosis with EES) are maintained or further increase with longer-
term follow-up is unknown. Finally, while no significant differences were
present between the 2 stent types in patients with diabetes mellitus at 1
year, whether important differences will emerge with longer term fol-
low-up is unknown.
Methods: In SPIRIT IV, 3,687 patients at 66 U.S. centers were prospec-
tively randomized 2:1 to EES vs. PES, stratified by diabetes and lesion
complexity. Patients with up to 3 de novo native coronary artery lesions
(maximum 2 lesions per epicardial vessel) with length 28 mm and
reference vessel diameter 2.5 mm to 4.25 mm were enrolled. Routine
angiographic follow-up was not performed.
Results: At 1 year, EES compared to PES resulted in reduced rates of TLF
(4.2% vs. 6.8%, P0.001), ID-TLR (2.5% vs. 4.6%, P0.001), stent
thrombosis (0.3% vs. 1.1%, P0.004) and MI (1.9% vs. 3.1%, P0.02).
The 2-year results for all patients (including the diabetic subgroup) will be
available for first presentation at TCT2010.
Conclusions: SPIRIT IV is the largest randomized trial to date comparing
two drug-eluting stents. The 2-year outcomes from this trial will provide
important insights into the absolute and relative long-term safety and
efficacy outcomes of the EES and PES platforms in a complex patient
population, including 1185 randomized patients with diabetes.
COMPARE Trial
Pieter Cornelis Smits, MD, Elvin Kedhi, MD,
Kaiyum Sheik Joesoef, MD, Eugene McFadden, MD,
Jochem Wassing, MD, Cees-Jan Royaards, MD, Jaenine Schaaf, RN.
Background: The COMPARE Trial is a physician initiated, prospective,
randomized, controlled trial comparing the outcome of the everolimus
eluting Xience stent versus the paclitaxel eluting Taxus Liberte´ stent in an
all-comer population.
Methods: 1800 patients were enrolled and randomized. Patients received
dual antiplatelet therapy (DAPT) till 12 months. The primary endpoint
(composite of all death, non fatal MI and clinically driven TVR) was
presented at the LBT session of TCT 2009 and the study outline, method-
ology and 1 year results were published in the Lancet 16 January 2010.
Mid-long term outcome of the everolimus eluting stent compared to
second generation paclitaxel eluting Taxus Liberte´ stent is unknown, spe-
cially when patients are not receiving DAPT anymore. Furthermore, of
interest is to see whether the low stent thrombosis rate (according to ARC)
of the everolimus eluting Xience stent in an all-comer population will
remain after 1 year. We will report on the two year follow-up results of the
primary and secondary endpoints definitions of the COMPARE trial. Also
a sub-analysis on the DM population and patients presenting with an acute
coronary syndrome will be reported
Results: After 1 year all patients were followed by questionaires and
telephone calls at 2 years FU. Information on hospital admissions and
medication usage were obtained. Monitoring of hospital records was done
in case of hospitalization. All revascularizations were analyzed by an
indenpendent core lab and all events adjudicated by an independent clinical
event commitee.
Conclusions: The 2 year follow-up and analysis is ongoing and will be
ready for TCT 2010.
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Zilver PTX: A Prospective, Randomized Trial of the Polymer-Free
Paditaxel-Eluting Stent Compared to Balloon Angioplasty with
Provisional Bare Metal Steating in Patients with Superficial Femoral
Artery Disease
Michael Dake, M.D, Gary Ansel, M.D., Michael Jaff, D,0.,
Takao Ohki, M.D, Ph.D, Richard Saxon, M.D., H.Bob Smouse, M.D.,
Lindsay Machan, M.D., Thomas Zeller M.D., Gary Roubin, M.D.,Ph.D.,
Mark Burket, M,D., Yazan Khatib, M.D., Scott Snyder PhD,
Anthony Ragheb, Ph.D., and J. King White, M.D., for the Investigators
Background: The Zilver® PTX® is the first drug-eluting stent approved
(currently CE marked, investigational in the U.S.) for the superficial fem-
oral artery (SFA). This multicenter, multinational, prospective, randomized
study compared the safety and effectiveness of the Zilver PTX to balloon
angioplasty (PTA) and bare metal stenting (BMS).
Methods: Patients-with de novo or restenotic SPA lesions were random-
ized to PTA or Zilver PTX stent placement. PTA patients experiencing
acute failure (30%residual stenosis) underwent secondary randomization
to provisional stenting with Zilver BMS or Zilver PTX. Endpoints included
event-free survival (EFS), stent integrity by radiographic core laboratory
analysis, and primary patency by Duplex ultrasound core laboratory anal-
ysis (peak systolic velocity ratio  2.0).
Results: 479 patients were enrolled at 56 institutionsin the United States,
Japan and Germany, withy 241 patients randomized to the Zilver PTX
group and 238 to the PTA group. Demographics and lesion characteristics
were similar for the groups. Approximately half the PTA group experi-
enced acute failure and underwent secondary randomization, assigning 59
and 61patients to provisional stenting with Zilver BMS axid Zilver PTX,
respectively.
Conclusions: The 12-month primary endpoint results of this randomized,
multicenter study of the safety and effectiveness of the Zilver PTX Drug-
Eluting Peripheral Stent will be presented at TCT.
A Prospective Randomized Trial of Everolimus-Eluting and
Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
(SORT OUT IV trial)
Lisette Okkels Jensen MD, DMSci, PhD, Per Thayssen MD, DMSci,
Henrik Steen Hansen MD, DMSci, Evald Høj Christiansen MD, PhD,
Hans Henrik Tilsted MD, Lars Romer Krusell MD,
Anton Boel Villadsen MD, Anders Junker MD, PhD,
Knud Nørregaard Hansen MD, Anne Kaltoft MD, PhD,
Michael Maeng MD, PhD, Knud Erik Pedersen MD, DMSci,
Steen Dalby Kristensen MD, DMSci,
Hans Erik Bøtker MD, DMSci,PhD, Jan Ravkilde MD, DMSci,
Richardo Sanchez MD, Jens Aarøe MD, Morten Madsen MSc,
Henrik Toft Sørensen MD, DMSci, PhD, Leif Thuesen MD, DMSci,
Jens Flensted Lassen MD, PhD
Background: The sirolimus-eluting stent has demonstrated the least
amount of late lumen loss among previously released drug-eluting stents,
but its safety and efficacy have not been compared head-to-head with the
next-generation everolimus-eluting stent.
Methods: The Scandinavian Organization for Randomized Trials with
Clinical Outcome (SORT OUT) IV trial was designed as a randomized
multicenter, open-label, all-comer, two-arm, non-inferiority study compar-
ing the everolimus-eluting stent with the sirolimus-eluting stent in patients
with coronary artery disease. The primary endpoint was a combination of
9-month safety (cardiac death, myocardial infarction, definite stent throm-
bosis) and efficacy (target vessel revascularization) parameters. Analysis
was by intention-to-treat. Data on clinical events and mortality subsequent
to randomization were obtained from national databases. No clinical fol-
low-up examinations were scheduled as part of the study.
Results: 1,392 patients (with 1,808 lesions) were assigned to receive the
everolimus-eluting stent, and 1,385 patients (with 1,780 lesions) were
assigned to receive the sirolimus-eluting stent. The primary endpoint will
be presented at TCT 2010.
Two-Year Clinical and Angiographic Outcomes From a Stratified
Randomized Controlled Trial of Everolimus -Eluting Xience Stents
Versus Sirolimus-Eluting Cypher Stents in Patients With Coronary
Artery Disease enrolled in the ISAR-TEST-4 Trial
Robert A. Byrne, MB BCh; Adnan Kastrati, MD; Klaus Tiroch, MD;
Steffen Massberg, MD; Anna Wieczorek; Karl-Ludwig Laugwitz, MD;
Stefanie Schulz, MD; Ju¨rgen Pache, MD; Massimiliano Fusaro, MD;
Melchior Seyfarth, MD; Albert Scho¨mig, MD; Julinda Mehilli, MD
Background: Clinical trials with the everolimus-eluting stent (EES;
Xience) have yielded promising results. In head-to-head randomized trials,
EES has proven superior to the paclitaxel-eluting stent (Taxus). However,
a more appropriate comparator device is the sirolimus-eluting stent (SES;
Cypher) due to its high antirestenotic efficacy and its similar limus-based
elution strategy.
Methods: In the setting of the Intracoronary Stenting and Angiographic
Results: Test Efficacy of Limus Eluting Stents (ISAR-TEST-4) trial, 1304
patients with de novo native coronary artery disease were randomized in a
stratified manner to receive either EES (n652) or SES (n652). Clinical
follow-up was performed out to 2 years. Angiographic follow-up was
scheduled at 6-8 months and at 2 years.
The primary endpoint is the device-oriented composite of cardiac death,
myocardial infarction (MI) related to the target vessel and target lesion
revascularization (TLR) at 2 years. The secondary endpoints are the indi-
vidual components of the primary endpoint as well as definite/probable
stent thrombosis, binary angiographic restenosis and late luminal loss at 2
years.
Results: Two-year angiographic and clinical results will be available for
first presentation at TCT 2010.
Conclusions: Two-year results from the randomized comparison of
everolimus-eluting Xience stents versus sirolimus-eluting Cypher stents
will shed important light on comparative outcomes of the leading first- and
second generation drug-eluting stents as well as provide direct insight into
the relative late performance characteristics of both devices.
Randomized Comparison of Rapamycin/probucol with Zotarolimus-
eluting Stent in Patients with Symptomatic Coronary Artery Disease
Julinda Mehilli, Klaus Tiroch, Stefanie Schulz, Ju¨rgen Pache,
Steffen Massberg, Robert A. Byrne, Karl-Ludwig Laugwitz,
Melchior Seyfarth, Jo¨rg Hausleiter, Albert Scho¨mig, Adnan Kastrati
Background: Permanent polymers have often been a source of concern
regarding mid- and long-term safety of drug-eluting stents (DES). The
polymer-free rapamycin/probucol-eluting stent (Dual-DES) is unique in its
design, making use of proprieties of two different drugs without recurring
to polymer. Dual-DES has been shown to yield angiographic outcomes
comparable or even better than those of permanent-based limus-eluting
stents. However, no large scale randomized trials powered for clinical
endpoints have assessed the role of Dual-DES compared to permanent
polymer-based DES. In the Intracoronary Stenting and Antirestenotic Re-
sults: Test Efficacy of Rapamycin/Probucol- and Zotarolimus-Eluting
Stents (ISAR-TEST-5) trial we aimed to randomly assess one-year clinical
performance of Dual-DES with zotarolimus-eluting stent (Endeavor Res-
olute – ER) in an all-comer population.
Methods: In this study patients were included if older than 18 years with
ischemic symptoms or evidence of myocardial ischemia in the presence
of  50% de novo stenosis located in native coronary vessels. Excluded
were patients with need for left main, with in-stent restenosis, cardiogenic
shock, malignancies or other comorbid conditions with life expectancy less
than 1 year. There was a 2:1 randomization between the Dual-DES group
and the ER stent group.
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The primary endpoint of the trial is the FDA-recommended combined
endpoint of cardiac death, myocardial infarction related to the target vessel
or revascularization related to the target lesion at 1-year follow-up. Sec-
ondary endpoints are: in-segment binary restenosis and in-stent late lumen
loss at follow-up angiography; all cause mortality and incidence of stent
thrombosis (by ARC definition) over 1 year. Enrollment of the planned
total number of 3002 patients has been completed and 1-year follow-up of
the last patient will be done at the end of July 2010.
Results: Data regarding the primary and secondary endpoints will be
presented at the TCT meeting.
A Prospective, Multicenter Randomized Trial of Heparin Plus
Glycoprotein IIb/IIIa Inhibitors vs. Bivalirudin, and Drug-eluting
vs. Bare Metal Stents in ST-Segment Elevation Myocardial
Infarction: Final report from the HORIZONS-AMI Trial
Gregg W. Stone, Bernhard Witzenbichler, Giulio Guagliumi,
Jan Z. Peruga, Bruce R. Brodie, Dariusz Dudek, George Dangas,
S. Chiu Wong, Eugenia Nikolsky, Louise Gambone, Lynn Vandertie,
Helen Parise, Alexandra J. Lansky and Roxana Mehran
for the HORIZONS-AMI Trial Investigators
Background. Selection of optimal pharmacology and stent type is essential
to enhance event-free survival in patients undergoing primary PCI for
AMI. Long-term data after allocation of patients with STEMI to different
antithrombotic regimens and stents are limited. HORIZONS-AMI was a
large-scale, prospective, international randomized trial of heparin plus
glycoprotein IIb/IIIa inhibitors (GPI) vs. bivalirudin, with a second ran-
domization of stent eligible patients to DES vs. BMS in STEMI. We herein
report the final 3-year results from this investigation.
Methods. In the HORIZONS-AMI trial, 3,602 patients with STEMI within
12 hours of symptom onset undergoing primary PCI were randomized in a
1:1 ratio at 123 international centers to heparin plus a GPI or (n1,802) or
bivalirudin alone (n1,800). Following coronary arteriography, 3,006 pa-
tients eligible for stent implantation were randomized again in a 3:1 ratio
to paclitaxel-eluting stents (PES; n2,257) or otherwise identical bare
metal stents (BMS; n749). Follow-up was initially planned for 5 years,
but an administrative decision was made to terminate follow-up after 3
years.
Results. At 1 year, bivalirudin alone compared to heparin plus GPI resulted
in reduced rates of major bleeding (5.8% vs. 9.2%, P0.0001), comparable
rates of reinfarction and TVR, and significantly lower 1-year rates of
cardiac mortality (2.1% vs. 3.8%, P0.005) and all-cause mortality (3.4%
vs. 4.8%, P0.03). At 1-year PES compared to BMS resulted in reduced
rates of TLR (4.5% vs. 7.5%, P0.002) with similar rates of the composite
safety endpoint of death, MI, stroke or stent thrombosis (8.1% vs. 8.0%,
P0.92), death (3.5% vs. 3.5%, P0.98) and stent thrombosis (3.1% vs.
3.4%, P0.72). At 13 months angiographic restenosis was significantly
reduced with PES compared to BMS (10.0% vs. 22.9%, P0.001).
Conclusions. HORIZONS-AMI is the largest completed randomized trial
of different pharmacologic regimens and stent types in STEMI. At 1-year
bivalirudin alone compared to heparin plus GPI resulted in significantly
reduced rates of major bleeding and mortality, while PES compared to
BMS safely reduced clinical and angiographic restenosis. The final 3 year
outcomes from this trial will be presented for the first time at TCT 2010,
and will determine whether these results are maintained with longer-term
follow-up.
Repeat Treatment Strategies for Drug-Eluting Stent Restenosis:
One-Year Results from CRISTAL, A Prospective Randomized
Study Comparing Re-PTCA with Cypher Sirolimus-Eluting Stent
Implantation
Bernard Chevalier, MD on behalf of the CRISTAL Investigators
Background: Restenosis following drug-eluting stent implantation is a
rare and poorly investigated clinical setting. Possible treatment strategies
range from simple balloon angioplasty to implantation of another drug-
eluting stent. No randomzed clinical studies were conducted so far to
investigate the outcomes of either of these treatment options.
Methods: The CRISTAL study sought to test two hypotheses:
1) Implantation of a new Cypher stent is superior to repeat balloon
angioplasty in patients with restenosis in Cypher stents (group 1, n120),
and in Taxus stents (group 2, n120).
2) At the time of restenosis, there will be no difference between the two
groups in the response to either treatment modality (non-inferiority com-
parison).
As a reference, patients with bare-metal stent restenosis (group 3, n80)
were treated with a new Cypher stent but not with balloon angioplasty as
a previous investigation (ISAR-DESIRE) had shown poor results for such
treatment.
Randomization was 2:1 (Cypher:PTCA) in group 1 and 2. The primary
endpoint in each group was in-stent late lumen loss at 12 month follow-up.
Secondary endpoints included rates of procedural success, death, myocar-
dial infarction, and target lesion revascularization at 1 year. The study was
conducted at 37 study sites in France. An independent angiographic core
lab (Bio-Imaging, Leiden, The NL) analyzed all baseline and follow-up
angiographic films using QCA methodology.
Results: The planned study population size was 320. Due to slow recruit-
ment, enrollment was stopped at 281 patients (group 1: n108, group 2:
n89, group 3: n84). Mean age was 66.6 y, 32.7% of patients were
diabetic, 69.4% had arterial hypertension, 76.9% had hyperlipidemia, and
64.1% were current or previous smokers. 31.3% had a history of previous
myocardial infarction, and 7.8% had received coronary artery bypass
grafts. Analysis of the angiographic data is ongoing.
Conclusion: Primary endpoint results will be available for presentation at
the conference.
LANCELOT ACS: A Prospective, Randomized, Double-Blind,
Placebo-Controlled Trial of a Reversible PAR-1 Thrombin Receptor
Antagonist in Patients with Acute Coronary Syndromes
Michelle L. O’Donoghue MD, MPH, Deepak L. Bhatt MD, MPH,
Stephen D. Wiviott MD, Shaun G. Goodman MD, Shinya Goto MD,
Gilles Montalescot MD, PhD, Rafal Ziecina MD,
Charles F. Contant PhD, Marcus D. Flather MD,
on Behalf of the LANCELOT Investigators
Background: Thrombin stimulates platelet activation and plays a central
role in thrombosis. E5555 is a reversible PAR-1 thrombin receptor antag-
onist that interferes with PAR-1 activation and platelet signaling. The
primary objective of the multicentre, international, phase II LANCELOT-
ACS trial (clinicaltrials.gov NCT00548587) was to evaluate the safety and
tolerability of E5555 in patients after non-ST-elevation ACS (NSTE-ACS).
Methods: Subjects were randomized within 72 hours of NSTE-ACS to one
of 3 dosing levels of E5555 (400mg loading dose followed by 50mg QD,
100mg QD or 200mg QD) or matching placebo. Subjects were to be treated
for 12 weeks and followed for an additional 4 weeks. The primary safety
endpoint was major bleeding according to the CURE classification. Sec-
ondary objectives included the effect of E5555 on efficacy, including
cardiovascular death, myocardial infarction, stroke and recurrent ischemia
(MACE). Platelet aggregation and Holter-based ischemia were assessed at
serial timepoints. The study was performed in accordance with local ethics
regulations and all subjects provided informed consent.
Results: 603 subjects were randomized to one of the 4 treatment arms and
593 subjects took at least 1 dose of study drug. The mean age of subjects
was 62 years and 32% were female. The qualifying event was NSTEMI in
75% of subjects. 96% were treated with aspirin and 78% received dual
antiplatelet therapy with aspirin in combination with clopidogrel or ticlo-
pidine. Presented results will include the incidence of bleeding (according
to the CURE and TIMI classification) and MACE. Additional outcome
measures will include the incidence of Holter-based ischemia, TRAP-
induced platelet inhibition and adverse effects. These results will provide
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insight into the potential utility of E5555 in the management of patients
after ACS.
A Prospective, Multicenter, Single Blind, Randomized, Controlled
Trial Comparing the Lutonix Catheter vs. Standard Balloon
Angioplasty for Treatment of Femoropopliteal Arteries With and
Without Stenting (LEVANT I)
Dierk Scheinert, Thomas Zeller, Stephan Duda, Hans Krankenberg,
Jens Ricke, Marc Bosiers
Background: Standard of care treatment for peripheral arterial disease
(PAD) with standard balloon angioplasty and stenting is complicated by
restenosis. This study assesses the safety and efficacy of a novel drug-
coated angioplasty balloon catheter for the treatment of femoropopliteal
disease.
Methods: One hundred-one patients were prospectively randomized in a
single-blind multicenter study to compare the safety and efficacy of a
paclitaxel plus excipient coated balloon catheter (sponsor Lutonix, Min-
nesota USA, NCT#00930813) versus an uncoated balloon catheter. Pa-
tients were stratified prior to randomization into stent or non-stent groups.
The primary endpoint was angiographic late lumen loss at 6 months post
treatment.
Results: Baseline demographics and lesion characteristics were similar
between groups. Mean lesion length of the lesion by visual estimate of the
Investigator was 8.73.7 cm.
Conclusions: Thirty day safety data was equal between the test and control
groups. Six month angiographic and clinical data will be presented.
PERfECT STENT: A ProspEctive, Randomized Trial Evaluating a
Paclitaxel-Eluting Balloon in Patients Treated with Endothelial
Progenitor Cell CapTuring Stents for De Novo Coronary Artery
Disease
Jochen Wo¨hrle, Ralf Birkemeyer, Sinisa Makrovic, The-Vinh Nguyen,
Anil Sinha, Tomislav Miljak, Jochen Spiess, Wolfgang Rottbauer,
Armin Imhof, Harald Rittger
Background: Rapid endothelialisation of coronary stents by capturing of
endothelial progenitor cells in combination with an abluminal antiprolif-
erative drug release for reduction of neointimal formation represents in
principle the optimal combination for treatment of coronary artery stenosis.
Rapid endothelialisation has been shown with the endothelial progenitor
cell capturing stent (Genous stent, OrbusNeich). Local delivery of pacli-
taxel with a drug-eluting balloon exerts a homogenous drug-delivery. The
paclitaxel eluting SeQuent Please balloon catheter (B.Braun Melsungen
AG, Germany) has shown to be effective by reducing neointimal prolifer-
ation in in-stent restenosis and lesions in small coronary vessels.
We evaluated in a randomized, mutlicenter, single blinded trial, whether
treatment with the Genous stent plus paclitaxel-eluting balloon catheter is
superior to Genous stent alone.
Methods: 120 patients with a de-novo lesion in a native coronary artery
with indication for percutaneous coronary intervention with a reference
diameter ranging from 2.5mm to 4.0mm were included in three centers.
Patients were stratified according to the presence of diabetes mellitus.
Exclusion criteria were: lesion in grafts, chronic total occlusion, bifurcation
lesion, left main lesion, restenosis and in-stent restenosis, contraindication
for acetylsalicylic acid or clopidogrel. The length of the paclitaxel eluting
balloon was chosen to overlap the stent for at least 1mm at the proximal
and distal margin. All patients were scheduled for control angiography at
6 months.
The hypothesis is that Genous stent implantation plus paclitaxel-eluting
balloon therapy results in a lower in-stent late loss (primary endpoint)
compared to Genous stent implantation alone at 6 months angiographic
follow-up. Power was 80%, alpha 0.05. In-stent late loss was assumed to
be reduced by absolute 0.30mm, from 0.75mm with use of the Genous stent
alone to 0.45mm with use of the Genous stent plus paclitaxel-eluting
balloon. Secondary angiographic endpoints are binary restenosis, minimal
lumen diameter, diameter stenosis, late loss index at the target lesion and
at the total segment including the 5mm proximally and distally to the
stented segment. Secondary clinical endpoints are target lesion revascular-
ization, stent thrombosis according to ARC criteria, major adverse cardiac
events as a composite of cardiac death, target lesion revascularization and
myocardial infarction related to the target vessel. The trial is registered
(ClinicalTrials.gov number NCT00732953). Last angiographic follow-up
will be performed in August 2010.
Results and Conclusions: Angiographic and clinical 6 months data in-
cluding the primary endpoint (late loss at 6 months) will be presented for
the first time.
Percutaneous Endovenous Intervention Reduces Recurrent Venous
Thromboembolic Disease and Post-Thrombotic Syndrome in Acute
Proximal Deep Venous Thrombosis:- Report of the Thrombus
Obliteration by Rapid Percutaneous Endovenous Intervention in
Deep Venous Occlusion “TORPEDO” trial at Mid-Term Follow-up.
Mohsen Sharifi,MD,FACC, Gary Smith,MD, Curt Bay, PhD,
Mahshid Mehdipour, Jalaladdin Sharifi,MD
Background: Venous thromboembolism (VTE) is an under-diagnosed
disease spectrum with a high mortality and morbidity. Recurrent VTE and
post-thrombotic syndrome (PTS) are common complications of deep ve-
nous thrombosis (DVT) which can occur despite effective anticoagulation.
Recurrent DVT can occur in 20% of patients on oral anticoagulation, and
PTS in 50% of such patients at 2-5 years after the initial episode. There are
no randomized trials investigating the efficacy of percutaneous endovenous
intervention (PEVI) in the reduction of the above complications. We
compared the efficacy and safety of PEVI plus anticoagulation with anti-
coagulation alone in the reduction of the above complications in acute
proximal DVT.
Methods: A total of 183 patients with symptomatic proximal DVT were
randomized to receive PEVI plus anticoagulation (91 patients) or antico-
agulation alone (92 patients). Anticoagulation consisted of intravenous
unfractionated heparin or subcutaneous low molecular weight heparin plus
warfarin. PEVI consisted of one or more of a combination of thrombec-
tomy, balloon venoplasty, stenting or local low-dose thrombolytic therapy.
All received compression stockings at 30-40 mmHg.
Results: The duration of follow-up was 12-41 months with a mean of
305 months. There were 88 patients in the PEVI Group and 81 patients
in the anticoagulation - alone Group who reached this follow-up. The
development of recurrent VTE and PTS between the two groups will be
described.
Conclusions: The first prospective randomized controlled trial of the
efficacy of PEVI in the reduction of VTE and PTS due to DVTat a mean
follow-up of 305 months has been completed. The mid-term results will
be reported at TCT 2010.
Sirolimus-eluting Stents versus Bare-Metal Stents For Treatment of
Infrapopliteal Arteries: A Double Blind, Multi-Centre Randomised
Clinical Trial
Aljoscha Rastan, MD, Gunnar Tepe, MD, Hans Krankenberg, MD,
Rainer Zahorsky, MD, Uwe Schwarzwa¨lder, MD, Elias Noory, MD,
Ullrich Beschorner, MD, Sebastian Sixt, MD, Thomas Schwarz, MD,
Karlheinz Bu¨rgelin, MD, Klaus Brechtel, MD, Thilo Tu¨bler, MD,
Roland Macharzina, MD, Franz-Josef Neumann, MD, and
Thomas Zeller, MD
Background: Preliminary reports indicate that sirolimus-eluting stents
reduce the risk of restenosis after percutaneous infrapopliteal artery revas-
cularization
Methods: We conducted a prospective, randomized, multi-centre, double
blind trial comparing a polymer-free sirolimus-eluting stent with a bare-
metal stent in 161 patients with either intermittent claudication or critical
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limb ischemia who had a de-novo lesion in an infrapopliteal artery. The
main study endpoint was the 1-year primary patency rate, defined as
freedom from in-stent-restenosis (luminal narrowing of 50%) detected
with angiography or if appropriate with duplex ultrasound. Secondary
endpoints included the 6-month primary patency rate, secondary patency
rate, changes in Rutherford-Becker classification and ankle-brachial index.
Between April 2006 and April 2008, 82 patients were randomly assigned
to receive the polymer-free sirolimus-eluting stent, and 79 were assigned to
receive the bare-metal stent. With exception of a significantly higher
body-mass-index in the sirolimus-eluting stent group, the two groups were
similar with respect to all baseline variables examined. Overall, 67 percent
of the patients were men, and the mean age was 739 years. Forty-seven
percent (n75) of the patients suffered from critical limb ischemia (Ruth-
erford-Becker 4 or 5), 53% (n86) were claudicants (Rutherford-Becker 2
or 3). The mean target lesion length was 319 mm, with a mean reference
vessel diameter of 3.00.4 mm. Thirty-five occlusions were treated (Table 1).
TABLE 1. Baseline Characteristics of the Overall Patient Population
And of Each Treatment Group*
All Patients
(N161)
Sirolimus
Stent
(N82)
Bare Metal
Stent
(N79)
Age (years) 72.99 73.48 72.39
Male sex (%) 66.5 67.9 64.9
Body-mass-Index 274 285 274
Diabetes mellitus (%) 53.8 56.8 50.6
Dyslipidemia (%) 76.6 76.5 76.6
Hypertension (%) 89.9 91.4 88.3
Current smoker (%) 28.5 28.4 28.6
Renal insufficiency (%) 35.4 35.8 35.1
(Creatinine 1.5 mg/dl)
Critical Limb ischemia (%) † 46.6 51.2 41.8
Target lesion (%)
Anterior tibial artery 27 22 31
Tibioperoneal trunk 37 42 33
Peroneal artery 21 19 23
Posterior tibial artery 15 17 13
*Plus-minus values are means SD. There were no significant differences
between the treatment groups except for body-mass-index (P0.044).
†Critical limb ischemia was defined according to the Rutherford-Becker
classification.
The Biorest Liposomal Alendronate with Stenting Trial (BLAST):
Does a Monocyte-Specific Inhibitor Reduce Restenosis after Bare
Metal Coronary Stents?
Shmuel Banai, Ariel Finkelstein, Yaron Almagor, Abid Assali,
Yonathan Hasin, Uri Rosenschein, Patricia Apruzzese,
Alexandra J Lansky, Teruyoshi Kume, Martin B Leon
Background: Balloon angioplasty and bare metal stents (BMS) are asso-
ciated with frequent restenosis (RES). Transient drug release from drug
eluting stents (DES) reduces RES, but is challenged by continued safety
concerns, prolonged need for dual anti-platelet therapy (DAPT), and lim-
ited efficacy in certain lesions and high risk patients. Experimental and
human studies indicate that there is over-activation of circulating mono-
cytes after vascular injury, which contributes to neointimal hyperplasia and
RES after interventional procedures. LABR-312 is a unique intravenous
formulation designed specifically to reduce RES after interventional vas-
cular therapies. LABR-312 has site-specific anti-inflammatory and anti-
proliferative actions due to transient modulation of circulating monocytes
for several days, which permanently reduces accumulation of these cells at
vascular injury sites and around stent struts, attenuates downstream sig-
naling, and decreases neointimal hyperplasia. The unique monocyte-tar-
geting mechanism of action completely spares endothelial cells, allowing a
normal healing response and a standard BMS course of DAPT. In a
previous first-in-man study, there were no MACE, at one and 6 months
after a single infusion of LABR-312 concurrent with BMS therapy.
Methods: The BLAST Phase II trial is a randomized, multicenter, double-
blind, placebo-controlled study in patients with significant stenoses in
native de novo coronary arteries treated with the Presillion™ cobalt alloy
BMS. Patients were randomized 1:1:1 to receive LABR-312 at two dose
levels (low dose 0.001 mg and high dose 0.01 mg) or placebo as an
intravenous infusion during the BMS procedure. All patients were assigned
to angiographic follow-up at 6 months and 50% of patients were selected
to be followed with intravascular ultrasound (IVUS) imaging during the
procedure and at 6 months. The primary endpoint was in-stent late loss
determined using quantitative techniques by an independent core angio-
graphic laboratory. Fluorescent activated cell sorter (FACS) analysis at
baseline and at 8, 16, and 24 hours after the procedure, and before
discharge quantified LABR-312 effects on circulating monocytes. Late loss
will be correlated with absolute number and relative changes in monocyte
number, activation state, and cytokine expression. The FACS responses to
LABR-312 may serve as a biomarker to predict and guide therapy out-
comes. DAPT was continued for 1 month after the procedure (or longer, at
the operator’s discretion).
Results: By intention-to-treat, 226 patients (253 treated lesions) were
enrolled at 12 investigational centers in Israel. For the overall study cohort,
mean age was 60.1 years, 88.9% were males, 33.8% had diabetes, and
60.9% had unstable symptoms. Baseline angiography: LV ejection fraction
57.4%, reference vessel diameter 2.77 mm, lesion length 13.03mm, and %
diameter stenosis 71.45% (reduced to 6.05% in-stent, after BMS placement).
Conclusions: The BLAST study will provide important insights on the
safety and effectiveness of LABR-312 as a systemic anti-RES therapy after
vascular intervention in patients with coronary stenoses. Importantly, the
novel use of this monocyte-specific inhibitor and the quantitative correla-
tion of angiographic and clinical effects along a biological continuum of
cellular modulation may change the paradigm of concomitant drug therapy
to prevent RES.
12-Month Angiographic Follow-up of the Novel Non-Polymeric
Biolimus A9-Coated Stent for the Treatment of De Novo Coronary
Lesions - Results from the Prospective, Multicenter, Randomized
BIOFREEDOM Clinical Trial
Eberhard Grube, Ricardo A. Costa, Alexandre Abizaid,
Joachim Schofer, Karl E Hauptmann, Gerhard Schuler,
Marco A. Magalhaes, Roxana Mehran, Peter Fitzgerald
Background: The BioFreedom (BF) Biolimus A9 (BA9) coated stent
(Biosensors Int., Singapore) is a new generation polymer-free drug-eluting
stent encompassing a 316L stainless steel platform that has been modified
with a proprietary surface treatment resulting in a selectively micro-struc-
tured abluminal surface. This technology allows adhesion of a potent
antiproliferative agent (BA9) to the stent’s abluminal surface and further
controlled release of the drug without the use of a polymer or binder. We
report the results of the first-in-man evaluation of the BF BA9-coated
stents, which were available in 2 different formulations: standard dose (SD:
15.6g/mm) and low dose (LD: 7.8g/mm).
Methods: 180 pts w/ single coronary lesion were included in the prospec-
tive, multicenter (4 sites in Germany), randomized (1:1:1 ratio) BIOFREE-
DOM trial. Pts were treated with the BF-SD (n60), BF-LD (n60) vs.
Taxus paclitaxel-eluting stents (PES) (n60). Lesion criteria were native
vessels 2.25-3.0mm in diameter, and 14mm in length. Overall, pts were
divided into 2 cohorts keeping the same randomization ratio: 1st cohort
(n75), enrolled in Sep/08-Jan/09, assigned for angiographic FU at
4-month; and 2nd cohort (n105), enrolled in Jan-Jun/09, assigned for
angiographic FU at 12-month. Primary endpoint was in-stent late lumen
loss (LLL) at 12-month FU (2nd cohort). Secondary endpoints were: in-
stent LLL at 4-month FU (1st cohort), in-stent restenosis and MACE at 4-
and 12-month FUs (1st and 2nd cohorts).
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Results: Baseline characteristics were comparable among the 3 groups;
38% of lesions were located in LAD, and all pts achieved angiographic
success. Overall, there were no safety concerns. Complete late clinical and
angiographic results including the larger cohort of pts undergoing 12-
month angiographic FU at 12-month will be presented at the meeting.
AVIO: A Prospective, Randomized Trial of Intravascular-
Ultrasound Guided Compared to Angiography Guided Stent
Implantation in Complex Coronary Lesions
Antonio Colombo; Christophe Caussin; Patrizia Presbitero;
Stefano Galli; Alberto Menozzi; Ferdinando Varbella; Fina Mauri;
Marco Valgimigli; Chourmouzios Arampatzis; Manuel Sabate;
Andrejs Erglis; Bernhard Reimers; Flavio Airoldi; Mikko Syvanne;
Ramon Lopez Palop; Ghada Mikhail; Philippe Mc Carthy;
Francesco Romeo; Azeem Latib and Alaide Chieffo
on behalf of the AVIO Investigators.
Background: The aim of this study was to demonstrate an advantage for
intra-vascular ultrasound (IVUS) optimized drug-eluting stent (DES) im-
plantation compared to angiography in complex lesions.
Methods: Study design: Multicentre, multinational, randomised, parallel
group, open label, investigator-driven study. All core-lab QCA and IVUS
measurements as well as data handling, monitoring, and clinical event
adjudication was performed independently by Mediolanum Cardio Re-
search (MCR), Milan, Italy. Patients with complex lesions (defined as
bifurcations, long lesions, chronic total occlusions or small vessels) were
randomized in a 1:1 ratio to IVUS optimized or angiographically guided
DES implantation. In the angiography group, a subgroup of 100 patients
was also randomised to undergo final IVUS. In the IVUS guided-group,
IVUS was performed after DES implantation in order to assess optimal
stent expansion which was based on the Optimal Balloon Size (OBS) that
would be used for post-dilatation. The OBS was determined by averaging
the media to media diameters at distal and proximal stent segments and at
the sites of maximal narrowing. Any segment inside the stent with a cross
sectional area (CSA) less than the target criteria for the OBS (see AVIO
criteria in Table) was considered underexpanded and postdilatation with a
non-compliant OBS was performed. Primary study end point was post-
procedure in lesion minimal lumen diameter (MLD). Secondary study end
points were the occurrence of target vessel revascularization (TVR) at 9
months and the occurrence of major adverse cardiac events (MACE) at 1,
6, 9 months.
Results: Two hundred and eighty five patients (285) were randomized into
the study. Of these, one was erroneously randomized but not treated. The
remaining 284 patients were randomized as follows: 142 in the IVUS
group and 142 in the angio group (93 angio and 49 angio  final IVUS).
No difference was observed in baseline clinical and lesion character-
istics.
Conclusions: The primary and secondary study end points will be pre-
sented as a “First Report” Investigation at TCT 2010 on September 25th
2010
TABLE. “AVIO” IVUS Criteria
Optimal Balloon
Size
Nominal Area
mm2
Target Area
mm2
2.50 4.91 4
3.0 7.07 6
3.5 9.62 8
4.0 12.56 10
4.5 15.90 12
Comparison of Everolimus-Eluting versus Sirolimus-Eluting Stents
for Coronary Revascularization: The EXCELLENT Randomized
Trial
Hyo-Soo Kim, MD, PhD on behalf of the EXCELLENT Investigators
Background. The everolimus-eluting stent (EES) is a newly developed
drug-eluting stent (DES) using the Multilink Vision® stent platform com-
bined with the drug everolimus contained in a polymer coating. Random-
ized trials have shown the superiority of the EES compared with the
paclitaxel-eluting stent (PES) regarding in-stent late loss (LL) and clinical
outcome. However, there have been no large scale prospective comparison
of the EES with the sirolimus-eluting stent (SES), which has shown the
least amount of LL among first generation DES. This study was performed
to directly compare efficacy of the Xience V®/Promus™ stent with the
Cypher Select® stent in a head-to-head manner.
Method. The EXCELLENT trial was a prospective, randomized, open
label, multi-center near all-comer trial to demonstrate the non-inferiority of
EES in comparison to SES in preventing LL at 9 months. The trial design
has been published previously and the trial is registered at clinicaltrials.gov
(NCT00698607). 1443 patients were randomized 3:1 to receive either EES
or SES. All patients were recommended to undergo routine follow-up
angiography at 9 months. The primary endpoint is in-segment LL at 9
months for comparison of type of stent. Secondary endpoints include all
death, cardiac death, nonfatal myocardial infarction (MI), target lesion
revascularization (TLR), target vessel revascularization (TVR), stent
thrombosis, target vessel failure (defined as the composite of cardiovascu-
lar death, MI, and clinically driven TVR), and target lesion failure (defined
as the composite of cardiovascular death, target vessel related MI, clini-
cally driven TLR) at 12 months. There were no significant differences in
baseline characteristics between the two study groups. The data was man-
aged by an independent data management center and all clinical events
were adjudicated by an independent clinical event adjudication committee.
Conclusion. We will present whether EES was non-inferior to SES in
preventing LL at 9 months (the primary outcome of the stent comparison),
and also present the 1-year clinical outcomes between EES and SES.
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